Approved for use through 07/31/2006. OMB 0651-0 031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no person

RANSMITTAL **FORM**

(To be used for all correspondence after initial filing)

are required to respond to a collection or	illiornation diless it displays a valid OMB control number.
Application Number	10/698,963
Filing Date	October 31, 2003
First Named Inventor	Kathryn Chung
Group Art Unit	1614
Examiner Name	
Attorney Docket No.	49321-103

PTO/SB/21 (08-03)

ENCLOSURES (check all that apply)							
☐ Fee Attached ☐ Amendment/Response ☐ After Final ☐ Affidavits/declaration(s) ☐ Extension of Time Request ☐ Express Abandonment Request ☐ Information Disclosure Statement; Form PTO/SB/08 ☒ Cited References (15) ☐ Certified Copy of Priority Document(s) ☐ Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 ☐ Response to Missing Parts/Incomplete Application ☐ Drawing(s) Request for Corrected Filir Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation, Change of Correspondence Address ☐ Declaration ☐ Statement under 37 CFR 3.73(b) ☐ Terminal Disclaimer ☐ Small Entity Statement ☐ Request for Refund ☐ Request for Refund		CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below): Copy of International Search Report for Application No. PCT/US03/34815					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Individual Name Jane E. R. Potter 22504							
Signature EKHOUT							
Date							
CERTIFICATE OF FACSIMILE TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date specified below.							
Typed or printed name	Jessica Gaunt						
Signature	Lessicabount	Date: April 30; 2004					

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 30, 2004

Date

Jessica Gaunt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Kathryn Chung et al.

Application No.

: 10/698,963

Filed

: October 31, 2003

For

: TREATMENT OF HYPERKINETIC MOVEMENT DISORDER WITH

DONEPEZIL

Docket No.

: 49321-103

Date

: April 30, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08 (copies of the cited references are enclosed). Twelve references were cited in the Search Report of the corresponding application, International Application No. PCT/US03/34815 (copies of the cited references are enclosed). Reference A is cited in the specification at page 1, line 27. Reference A is provided herewith, and corresponds to the database review cited in the specification. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants'

duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

> Respectfully submitted, Kathryn Chung et al. DAVIS WRIGHT TREMAINE LLP

Jane E. R. Potter

Registration No. 33,332

2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Phone: (206) 628-7650

Facsimile: (206) 628-7699

MAY 0 4 2004 &

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE uction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

Application Number 10/698,963
Filing Date Ocotober 31, 2003
First Named Inventor Kathryn Chung
Art Unit 1614
Examiner Name

Complete if Known

PTO/SB/08A (05-03)

STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 49321-103

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ^{2 (il known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-2002/0035128 A1	03-21-2002			
· <u> </u>		US-6,034,117	03-07-2000			
		US-5,633,238	05-27-1997			
		US-		<u> </u>		
		US-				
		US-		<u></u>		
		US-		<u> </u>		
		US-				
		US-				
		US-	<u> </u>			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	l	US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	7
milais it		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	7 ppincark of Orloa Document	Or Relevant Figures Appear	
		WO-01/66114 A1	09-13-2001			
		EP-1020469 A2	07-19-2000			
		WO-97/46527	12-11-1997			
		EP-0698390 A1	02-28-1996			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O 1 P E

MAY 0 4 2004

PTO/SB/08B (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Leverwork Reduction Age of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for including the state of the st				Complete if Known		
INIEO	DMATION	DIS	CLOSUBE	Application Number	10/698,963	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	October 31, 2003			
		First Named Inventor	Kathryn Chung			
		Art Unit	1614			
				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	49321-103	

1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AARSLAND ET AL., Donepezil for Cognitive Impairment in Parkinson's Disease: a Randomised Controlled Study, J NEUROL NEUROSURG PSYCHIATRY, 72:708-712, 2002.	
	HARDAN ET AL., A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder, JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 12(3):237-241, 2002.	
	TAMMENMAA ET AL., Cholinergic Medication for Neuroleptic-Induced Tardive Dyskinesia, COCHRANE DATABASE SYST. Rev., CD000207, 2002.	
	CAROFF ET AL., Treatment of Tardive Dyskinesia with Donepezil: A Pilot Study, J CLIN PSYCHIATRY, 62(10):772-775, 2001.	
	CAROFF ET AL., Treatment of Tardive Dyskinesia with Donepezil, J CLIN PSYCHIATRY, 62(2):128-129, 2001.	
	LITVAN ET AL., Randomized Placebo-Controlled Trial of Donepezil in Patients with Progressive Supranuclear Palsy, NEUROLOGY, 57:467-473, 2001.	
	WILENS ET AL., Adjunctive Donepezil in Attention Deficit Hyperactivity Disorder Youth: Case Series, JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 10(3):217-222, 2000.	
	MENDEZ ET AL., Use of Donpezil for Vascular Dementia: Preliminary Clinical Experience, J NEUROPSYCHIATRY CLIN NEUROSI, 11(2):268-270, 1999.	
		AARSLAND ET AL., Donepezil for Cognitive Impairment in Parkinson's Disease: a Randomised Controlled Study, J NEUROL NEUROSURG PSYCHIATRY, 72:708-712, 2002. HARDAN ET AL., A Retrospective Open Trial of Adjunctive Donepezil in Children and Adolescents with Autistic Disorder, JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 12(3):237-241, 2002. TAMMENMAA ET AL., Cholinergic Medication for Neuroleptic-Induced Tardive Dyskinesia, Cochrane Database Syst. Rev., CD000207, 2002. CAROFF ET AL., Treatment of Tardive Dyskinesia with Donepezil: A Pilot Study, J CLIN PSYCHIATRY, 62(10):772-775, 2001. CAROFF ET AL., Treatment of Tardive Dyskinesia with Donepezil, J CLIN PSYCHIATRY, 62(2):128-129, 2001. LITVAN ET AL., Randomized Placebo-Controlled Trial of Donepezil in Patients with Progressive Supranuclear Palsy, NEUROLOGY, 57:467-473, 2001. WILENS ET AL., Adjunctive Donepezil in Attention Deficit Hyperactivity Disorder Youth: Case Series, JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 10(3):217-222, 2000. MENDEZ ET AL., Use of Donepezil for Vascular Dementia: Preliminary Clinical Experience, J

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to compete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.